Associated Papers
Comprehensive pharmacogenomics profiling of the Serbian population.
Jelovac M et al.
Frontiers in Pharmacology, 2025
40166472 (PubMed )
Supplement: DataSheet1.xlsx › 3._WES
Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity.
Larrue R et al.
The Pharmacogenomics Journal, 2024
Maternal synapsin autoantibodies are associated with neurodevelopmental delay.
Bünger I et al.
Frontiers in Immunology, 2023
A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature.
Conti V et al.
Journal of Personalized Medicine, 2020
Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.
Froehlich TK et al.
International Journal of Cancer, 2015
Select a paper to view details